Frank Colombo, managing director at Viridian Capital Advisors, discusses the cannabis industry’s decreasing M&A activity and what it means.

- Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AlphaQuest LLC increased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 119.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 2,795 shares of ...